Incyte insider sales
WebFeb 8, 2024 · Incyte Reports 2024 Fourth Quarter and Year-end Financial Results and Provides 2024 Financial Guidance and Updates on Key Clinical Programs ... 2024 reflects an increase in net product sales as a ... WebMar 11, 2024 · Incyte's ruxolitinib, a type of non-steroidal anti-inflammatory medication called a JAK inhibitor, already makes up a major chunk of earnings, representing $2.22 billion of the company's $2.46 ...
Incyte insider sales
Did you know?
WebCompany profile for Incyte Corp. including key executives, insider trading, ownership, revenue and average growth rates. ... 1Y Sales Change 13.67% . WebFeb 7, 2024 · Incyte Reports 2024 Fourth Quarter and Year-end Financial Results, Provides 2024 Financial Guidance and Updates on Key Clinical Programs February 7, 2024 at 7:00 …
WebApr 15, 2024 · In other Incyte news, EVP Maria E. Pasquale sold 60,024 shares of the stock in a transaction on Monday, January 30th. The shares were sold at an average price of $84.74, for a total value of $5,086,433.76. Following the completion of the sale, the executive vice president now directly owns 68,524 shares of the company's stock, valued at … WebIncyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization …
WebAug 25, 2024 · The SEC charged Panuwat with insider trading in Incyte securities under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, based on a misappropriation theory ... WebApr 12, 2024 · Incyte Co. (NASDAQ:INCY – Get Rating)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $75.51, but opened at $73.48. Incyte shares last traded at $74.04, with a volume of 102,254 shares. Wall Street Analysts Forecast Growth Several research analysts have issued reports on the company. Cowen increased […]
WebApr 12, 2024 · Morgan Stanley boosted their price objective on shares of Incyte from $76.00 to $77.00 in a research report on Wednesday. ... Insider Buying and Selling at Incyte. ... The stock was sold at an average price of $84.74, for a total value of $5,086,433.76. Following the sale, the executive vice president now owns 68,524 shares in the company ...
Web206 rows · Feb 7, 2024 · The following insiders have sold INCY shares in the last 24 … sharm cresseyWebApr 11, 2024 · Insider Trading Selling Shares $5.68 M Sold Last Quarter Proj. Earnings Growth 37.99% From $3.29 to $4.54 Per Share See Full Details Overall MarketRank ™ 2.80 … sharm currencyWebWebsite: www.incyte.com Headquarters: Wilmington, DE Size: 501 to 1000 Employees Founded: 1991 Type: Company - Public (INCY) Industry: Biotech & Pharmaceuticals Revenue: $100 to $500 million (USD) Competitors: Genentech, Gilead Sciences, Vertex Pharmaceuticals Create Comparison population of lymington hampshireWebNov 2, 2024 · In Q3 2024 it had sales of $38 million, more than doubling its Q2 sales. Considerable time was devoted to discussing its sales ramp during the Q3 Incyte Analyst … sharm club reviewsWebApr 10, 2024 · Incyte’s 2024 sales guidance also indicates that “competitive dynamics could start to more meaningfully impact Jakafi’s trajectory,” Abrahams stated. The stock is … sharm club resortWebApr 10, 2024 · The Incyte Thesis: Setbacks in LIMBER and the recent competitor advancement underline “the need for better execution of life-cycle strategies to enable optimal revenue sustainment beyond the ... sharm clubWebIncyte Corp. 1801 Augustine Cut-Off Wilmington, Delaware 19803 Phone 1 302 498-6700 Industry Biotechnology Sector Health Care/Life Sciences Fiscal Year-end 12/2024 Revenue $2.99B Net Income... sharm climate